Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Cancer Immunol Res. 2013 Nov 12;2(2):154–166. doi: 10.1158/2326-6066.CIR-13-0027

Figure 3. Anti-tumor activities of FAP-CAR T cells in mice bearing flank tumors.

Figure 3

Syngeneic mice bearing (A) TC1, (B) LKR, (C) AE17.ova, (E) CT26, and (F) 4T1 tumors were injected intravenously with 10 million FAP-CAR or MigR1 T cells when the tumors reached ~100–150 mm3. Tumor measurements followed. (D) To test the target-specificity of FAP-CAR T cells, AE17.ova tumor cells were also injected into FAP-null C57BL/6 mice. FAP-CAR T cells were given 7 days later. * Denotes statistical significance between untreated, MigR1 and FAP-CAR-treated samples, p value < 0.05.